Darya Chudova Sells 13,664 Shares of Guardant Health (NASDAQ:GH) Stock

by · The Markets Daily

Guardant Health, Inc. (NASDAQ:GH – Get Free Report) CTO Darya Chudova sold 13,664 shares of the firm’s stock in a transaction on Monday, December 8th. The stock was sold at an average price of $105.04, for a total value of $1,435,266.56. Following the completion of the sale, the chief technology officer directly owned 54,480 shares of the company’s stock, valued at $5,722,579.20. The trade was a 20.05% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Darya Chudova also recently made the following trade(s):

  • On Monday, December 8th, Darya Chudova sold 9,271 shares of Guardant Health stock. The shares were sold at an average price of $106.00, for a total value of $982,726.00.

Guardant Health Price Performance

Guardant Health stock traded down $0.59 during midday trading on Wednesday, reaching $102.62. The company’s stock had a trading volume of 1,913,708 shares, compared to its average volume of 2,231,505. The stock’s 50-day simple moving average is $87.13 and its 200-day simple moving average is $64.63. Guardant Health, Inc. has a 52-week low of $29.91 and a 52-week high of $112.43. The stock has a market capitalization of $12.93 billion, a P/E ratio of -31.97 and a beta of 1.58.

Guardant Health (NASDAQ:GH – Get Free Report) last issued its quarterly earnings results on Wednesday, October 29th. The company reported ($0.39) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.09. During the same period in the previous year, the business posted ($0.88) EPS. The firm’s revenue was up 38.5% on a year-over-year basis. As a group, equities research analysts expect that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. Evercore ISI upped their price target on shares of Guardant Health from $68.00 to $90.00 and gave the company an “outperform” rating in a research note on Thursday, October 30th. Piper Sandler lifted their price objective on shares of Guardant Health from $60.00 to $90.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 22nd. Wolfe Research raised Guardant Health from a “peer perform” rating to an “outperform” rating and set a $75.00 target price on the stock in a research report on Thursday, September 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Guardant Health in a research note on Wednesday, October 8th. Finally, BTIG Research lifted their price target on Guardant Health from $80.00 to $100.00 and gave the stock a “buy” rating in a research report on Thursday, October 30th. Twenty-three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $80.86.

Get Our Latest Report on Guardant Health

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Driehaus Capital Management LLC acquired a new stake in shares of Guardant Health during the 1st quarter valued at about $82,349,000. Alyeska Investment Group L.P. purchased a new position in Guardant Health during the third quarter worth approximately $114,421,000. ARK Investment Management LLC grew its holdings in Guardant Health by 100.4% in the second quarter. ARK Investment Management LLC now owns 2,823,497 shares of the company’s stock valued at $146,935,000 after purchasing an additional 1,414,381 shares during the period. Invesco Ltd. grew its holdings in Guardant Health by 100.9% in the first quarter. Invesco Ltd. now owns 2,794,667 shares of the company’s stock valued at $119,053,000 after purchasing an additional 1,403,670 shares during the period. Finally, Norges Bank purchased a new stake in shares of Guardant Health in the second quarter valued at approximately $64,136,000. 92.60% of the stock is currently owned by institutional investors and hedge funds.

About Guardant Health

(Get Free Report)

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.

Featured Articles